Kintara Posts VAL-083 Data As Adjuvant Therapy In Newly-Diagnosed GBM Patients

Kintara Therapeutics Inc KTRA announced topline data results from the newly diagnosed adjuvant arm of its Phase 2 clinical study.
The Phase 2 trial is testing VAL-083 in glioblastoma multiforme (GBM) patients who have an unmethylated promoter of the methylguanine DNA-methyltransferase (MGMT) gene.
Progression-Free Survival (PFS) for the 36 efficacy evaluable patients is 10.0 months. Historical data for this patient population has demonstrated a PFS of 5.3-6.9 months.
The median overall survival is 16.5 months, with historical data of 12.7-16.0 months.
Consistent with prior studies, myelosuppression was the most common adverse event. One patient experienced a serious adverse event (SAE) possibly related to VAL-083.
The Company previously announced topline data results from the recurrent GBM arm of the study.
Related: Kintara Therapeutics Shows Encouraging Safety, Efficacy Data From Brain Cancer Study With VAL-083.
Price Action: KTRA stock is down 2.27% at $1.29 during the market session on the last check Wednesday.